Osteomodulin contributes to keloid development by regulating p38 MAPK signaling

Abstract

AbstractA keloid is a classic fibrotic skin disease characterized by excessive deposition of extracellular matrix (ECM). Osteomodulin (OMD) is a heterologous protein that is a part of osteoadherin and plays a role in modulating ECM deposition. In this study, we investigated the effects of OMD on ECM synthesis and the tumor‐like phenotype of keloid fibroblasts. We enrolled 10 patients with keloids and 10 age‐ and sex‐matched healthy individuals, whose keloid or normal skin tissues were collected during surgery. Real‐time quantitative polymerase chain reaction (qRT‐PCR), western blotting, and immunohistochemical staining were performed to analyze OMD expression in skin tissues. Cell transfection, CCK‐8 assay, EdU staining, Transwell assay, qRT‐PCR, western blotting, and immunofluorescence were performed to study the effects of OMD on primary keloid‐derived fibroblasts (KFs). OMD exhibited greater expression in human keloid specimens than in normal skin tissues. Consistently, higher expression of OMD was observed in KFs, compared to that in normal fibroblasts. Silencing OMD expression in transforming growth factor (TGF)‐β1‐treated KFs inhibited cell proliferation and migration, as well as collagen and fibronectin expression; however, overexpression of OMD had the opposite effect. p38 mitogen‐activated protein kinase (MAPK) was activated in keloid tissues but not in normal skin. OMD was positively correlated with p38 MAPK activation. Adding SB203580, p38 MAPK inhibitor, significantly reversed the effects of OMD on the regulation of KF phenotype. The high expression of OMD may contribute to hyperproliferation of KFs, their migration, and excess ECM synthesis in KFs via regulation of the p38 MAPK signaling pathway.